HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bar-Shalom, R. Articles by Front, D. Search for Related Content PubMed PubMed Citation Articles by Bar-Shalom, R. Articles by Front, D.

Gallium-67 Scintigraphy in Lymphoma with Bone Involvement

Departments of Nuclear Medicine, Oncology and Diagnostic Radiology, Rambam Medical Center
Faculty of Medicine and Rappaport Institute of Medical Research, Technion—Israel Institute of Technology, Haifa, Israel

Correspondence: For correspondence or reprints contact: Dov Front, MD, PhD, Department of Nuclear Medicine, Rambam Medical Center, Haifa 35254, Israel.

ABSTRACT

Both Hodgkin's and non-Hodgkin's lymphoma (NHL) may involve bone. Traditionally, ^99mTc-MDP bone scintigraphy has been used to detect such involvement. In recent years, ⁶⁷Ga scintigraphy has shown to be useful in monitoring treatment response in lymphoma. Although ^99mTc-MDP has not been found particularly useful for monitoring bone response to cancer treatment, we were interested in whether ⁶⁷Ga scintigraphy and SPECT could be used to monitor bone involvement with lymphoma. Methods: Gallium-67 and ^99mTc-MDP uptake were investigated in 20 patients with lymphoma involving the bone before treatment Gallium-67 scans were done in 16 patients for monitoring response to treatment in the bone lesions. Results: Gallium-67 studies diagnosed bone lesions in 19 of the 20 patients. Technetium-99m-MDP detected bone lesions in all patients investigated. In four patients, uptake by Ga-67 was more intense than ^99mTc-MDP and in another four patients ^99mTc-MDP uptake was more evident. Gallium-67, however, was useful in detecting other regions of involvement in 18 of the 19 patients with soft-tissue lymphoma lesions. Gallium-67 scintigraphy also correctly monitored bone response to treatment in all but one of the 16 patients who had ⁶⁷Ga scintigraphy after completing therapy. Conclusion: Gallium-67 uptake by lymphoma involving the bone can be used to monitor osseous response to treatment.

Key Words: lymphoma • bone • gallium-67 • technetium-99m-MDP • Hodgkin's disease

This article has been cited by other articles:

				E. Even-Sapir Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities J. Nucl. Med., August 1, 2005; 46(8): 1356 - 1367. [Abstract] [Full Text] [PDF]

				R. Bar-Shalom, N. Yefremov, N. Haim, E. J. Dann, R. Epelbaum, Z. Keidar, D. Gaitini, A. Frenkel, and O. Israel Camera-based FDG PET and 67Ga SPECT in Evaluation of Lymphoma: Comparative Study Radiology, May 1, 2003; 227(2): 353 - 360. [Abstract] [Full Text] [PDF]

				O. Israel, M. Mekel, R. Bar-Shalom, R. Epelbaum, N. Hermony, N. Haim, E. J. Dann, A. Frenkel, M. Ben-Arush, and D. Gaitini Bone Lymphoma: 67Ga Scintigraphy and CT for Prediction of Outcome After Treatment J. Nucl. Med., October 1, 2002; 43(10): 1295 - 1303. [Abstract] [Full Text] [PDF]

				K. A. Morton, J. Jarboe, and E. M. Burke Gallium-67 Imaging in Lymphoma: Tricks of the Trade J. Nucl. Med. Technol., December 1, 2000; 28(4): 221 - 232. [Abstract] [Full Text] [PDF]